Avalyn Pharma

Avalyn Pharma is a clinical-stage biotechnology company developing inhaled antifibrotic therapies for rare respiratory diseases, particularly pulmonary fibrosis, with lead candidates AP01 and AP02 being inhaled formulations of approved oral drugs pirfenidone and nintedanib designed to improve local lung efficacy while reducing systemic side effects. The Boston-based company raised $300 million in its Nasdaq IPO (ticker: AVLN) at $18 per share, achieving an $813 million fully diluted valuation.